NY-BOTIFY
13.12.2022 10:01:55 CET | Business Wire | Press release
Botify, the leading enterprise software company for performance-driven organic search, is closing out 2022 by appointing a series of global executive hires and company advisors. The decision comes in response to continued industry and company growth, illustrating the company’s commitment to driving innovation, delivering excellence across all areas of the business and supporting customers with every opportunity to leverage organic search as a high-impact performance marketing channel.
“I’m thrilled to welcome Brian Marin, Phil Young, Vincent Gonnot, A.J. Ghergich, and Steve Sadove to Botify as we expand how we help global brands improve how they are found in organic search,” said Botify CEO, Adrien Menard. “Each of these leaders will be extremely instrumental in supporting our continued growth and new announcements in the coming months. As we embrace widespread recognition of the impact organic search has on company performance, and define Botify’s next chapter to meet growing demand, I’m confident that together, we will do great things.”
Former Smartly.io executive Brian Marin joined in August as Senior Vice President of Global Services. In this newly created role, Marin will launch a consulting service practice and expand professional services to meet continued customer demand. A seasoned digital marketer, Marin brings decades of SaaS experience and a proven track record building and leading services functions for companies in hyper-growth mode.
Joining Marin’s growing team, Botify welcomed A.J. Ghergich as Vice President of Consulting Services to lead the rollout of Botify’s new consulting service offering. Ghergich brings more than 15 years of organic search and digital marketing experience consulting for Fortune 500 global brands.
Phil Young, Vice President of Sales of Northern Europe, joined Botify in July, focusing on leading sales teams across Northern Europe including the UK, Denmark, Finland, Sweden, and the Netherlands. Young will be working closely with the marketing and product teams to drive growth and ensure the highest success level for his teams. Young brings more than 25 years’ experience driving sales results and joins Botify from Sitecore, the leading provider of end-to-end digital experience software, where he was Area Vice President of Northern EMEA.
Focusing on European expansion, Vincent Gonnot also joined Botify as Vice President of Sales Central/South EMEA in December. Similar to Young, Gonnot will be working alongside the marketing and product teams to ensure optimal regional growth for the company. Gonnot has more than 20 years of international sales and management experience across large companies and startups.
Additionally, Steve Sadove, Principal at Stephen Sadove and Associates, has joined Botify as an advisor, helping to provide high-level counsel to inform the company’s continued growth trajectory. Throughout his career serving as CEO of several retail and consumer brands, Sadove has mastered a deep understanding of how leveraging the right technologies can transform the entire landscape for a business. He will be instrumental in helping Botify achieve amplified success as an essential solution across global organizations.
About Botify
Botify is a global, enterprise software company focused on enabling the most ambitious brands to leverage organic search as a high-impact, performance marketing channel. Powered by AI and a proprietary unified data model, Botify’s platform ensures web and mobile sites are optimized for search, the foundation of being found by consumers in today’s dynamic digital environment. As the leader in organic search innovation, Botify is trusted by more than 500 of the world’s most visible brands, including Expedia, L'Oréal, Crate & Barrel, and The New York Times, all of whom have succeeded in leveraging organic search for exponential, long-term results and revenue growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom